Cargando…

Algorithm for Bosniak 2F Cyst in Kidney Donation

Patient: Female, 54 Final Diagnosis: Multilocular cystic renal cell carcinoma with clear cells Symptoms: None Medication: — Clinical Procedure: Hand-assisted retroperitoneal donor nephrectomy Specialty: Transplantology OBJECTIVE: Unusual setting of medical care BACKGROUND: The Bosniak system for rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Minnee, Robert C., Kimenai, Hendrikus J.A.N., Verhagen, Paul, Von den Thüsen, Jan, Dwarkasing, Roy S., van der Wetering, Jacqueline, IJzermans, Jan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503233/
https://www.ncbi.nlm.nih.gov/pubmed/28663537
http://dx.doi.org/10.12659/AJCR.904045
Descripción
Sumario:Patient: Female, 54 Final Diagnosis: Multilocular cystic renal cell carcinoma with clear cells Symptoms: None Medication: — Clinical Procedure: Hand-assisted retroperitoneal donor nephrectomy Specialty: Transplantology OBJECTIVE: Unusual setting of medical care BACKGROUND: The Bosniak system for radiological classification of renal cysts offers a tool for surgical decision-making in clinical practice. Although 95% of Bosniak 2F cysts remain benign, a consensus on the management of Bosniak 2F cysts in kidney donation has not been developed. CASE REPORT: We present a donor with a Bosniak 2F cyst, who successfully donated her kidney after partial resection of the Bosniak 2F cyst. Postoperative pathology examination of the partially resected cystic wall revealed a multilocular cystic renal cell carcinoma. Postoperative pathology examination revealed a multilocular cystic renal cell carcinoma. Resection of the Bosniak 2F cyst provides 2 advantages: the recipient receives a new donor kidney and will be free of dialysis, and the donor will be free of surveillance. CONCLUSIONS: We present a practical guideline for kidney donors with Bosniak 2F cysts, balancing the risk of tumor transmission or recurrence with the benefit associated with organ transplantation, without compromising the risk of the donor and recipient. Further evaluation of this algorithm by longer follow-up and more studies is needed to prove its safety.